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Abstract Various dietary agents can modulate tumor inva-
s i vene s s . The cu r r en t s tudy exp lo red whe the r
selenoglycoproteins (SeGPs) extracted from selenium-
enriched yeast affect tumor cell homing and growth in the
brain. Mice were fed diets enriched with specific SeGPs
(SeGP40 or SeGP65, 1 mg/kg Se each), glycoproteins
(GP40 or GP65, 0.2–0.3 mg/kg Se each) or a control diet
(0.2–0.3 mg/kg Se) for 12 weeks. Then, murine Lewis lung
carcinoma cells were infused into the brain circulation.
Analyses were performed at early (48 h) and late stages
(3 weeks) post tumor cell infusion. Imaging of tumor progres-
sion in the brain revealed that mice fed SeGP65-enriched diet
displayed diminished metastatic tumor growth, fewer extrav-
asating tumor cells and smaller metastatic lesions. While ad-
ministration of tumor cells resulted in a significant upregula-
tion of adhesionmolecules in the early stage of tumor progres-
sion, overexpression of VCAM-1 (vascular call adhesion
molecule-1) and ALCAM (activated leukocyte cell adhesion
molecule) messenger RNA (mRNA) was diminished in
SeGP65 supplemented mice. Additionally, mice fed SeGP65
showed decreased expression of acetylated NF-κB p65, 48 h
post tumor cell infusion. The results indicate that tumor pro-
gression in the brain can be modulated by specific SeGPs.
Selenium-containing compounds were more effective than
their glycoprotein controls, implicating selenium as a potential
negative regulator of metastatic process.
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Introduction
Brain metastatic tumors are detected in 10–30 % of all cancer
patients. However, the incidence rates of brain metastasis are
increasing due to improved diagnostic methods and better
control of primary tumors, resulting in longer patient survival
[1, 2]. The treatment of brain metastasis requires a multidisci-
plinary team approach, but therapeutic options for patients
affected by the disease are still limited. Although our under-
standing of the process of brain metastasis formation remains
incomplete, the interactions between tumor cells and the brain
microenvironment are considered to be critical determinants
in their progression towards metastasis, dormancy, or clear-
ance [3, 4]. Principal in these events is the expression of cell
adhesion molecules (CAMs) on the surface of the brain endo-
thelium. Cell adhesion molecules are cell surface glycopro-
teins that are typically transmembrane receptors mediating
cell-cell or cell-matrix interactions and influencing tumor cell
adhesion, migration, and metastatic potential [3–5].
Selenium (Se) is an essential micronutrient with complex
effects on human biology. Although widely distributed
throughout the body, Se is particularly well maintained in
the brain; even upon severe dietary Se deficiency, Se levels
remain high in the brain as compared to other tissues [6, 7].
Importantly, changes in Se concentration in the blood and the
brain have been reported in patients suffering from brain dis-
eases, including brain tumors [8, 9].
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Experimental in vivo and in vitro studies have demonstrated
that supplemental Se could reduce the risk of certain types of
cancer and modulate many processes relevant to tumor biology
[9–11]. Although it is likely that Se acts through multiple path-
ways, the exact molecular mechanisms by which antitumor
activity of Se compounds are mediated remain unclear [11,
12]. The functions of Se in human physiology are largely me-
diated by selenoproteins (25 of such proteins are identified so
far), in which Se is incorporated as selenocysteine [13, 14].
Although the functions of most of these proteins are still being
investigated, approximately half of them have been shown to
participate in oxidoreductase reactions [14]. Indeed, it has been
demonstrated that Se incorporated into selenoproteins reduces
oxidative stress and limits DNA damage, both of which are
associated with decreased cancer risk [11, 15]. Other possible
mechanisms that may be involved in the anticancer and
antimetastatic properties of Se include alteration of carcinogen
metabolism, modulation of inflammatory and immune re-
sponses, regulation of the cell cycle, induction of apoptosis of
cancer cells, alterations of DNA methylation, and inhibition of
angiogenesis and tumor cell motility [11, 12, 15–18]. The effi-
cacy of Se supplementation is dependent on the dose and chem-
ical form of Se, as distinct forms of Se in various concentrations
can express dramatically different biological effects [11, 18,
19]. Moreover, research suggests that only patients with a low
Se status may benefit from additional Se intake, while individ-
uals whose plasma Se concentration is 122 μg/L or higher
could be adversely affected and should not be supplemented
with Se [19, 20].
Se-enriched yeast is the most common source of Se avail-
able commercially and is also the most widely used Se-
supplementation method in clinical trials [21]. We have re-
ported previously that dietary supplementation with selenized
yeasts markedly decreased growth of brain metastatic tumors
in mice [18]. We demonstrated in a subsequent in vitro study
that specific selenoglycoproteins extracted from Se-enriched
yeasts have the ability to attenuate adhesion of tumor cells to
human brain endothelium [22]. The aim of the current study
was to evaluate if selected selenoglycoprotein fractions could
modulate growth of brain metastatic tumors in vivo. We show
that tumor progression in the brain can be modulated by sup-
plementation with specific selenoglycoproteins. Decreased
activity of NF-κB and reduced expression of cell adhesion
molecules may be one of the mechanisms responsible for the
observed effects.
Materials and Methods
D122 Lewis Lung Carcinoma Cells
D122 Lewis lung carcinoma cells tagged with luciferase
(D122-Luc) were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) GlutaMax medium (Life
Technologies, Carlsbad, CA, USA), supplemented with
10 % fetal bovine serum (Thermo Scientific, Rockford,
IL, USA) and 1 % penicil l in/streptomycin (Life
Technologies). The cells were transfected with green fluo-
rescent protein (GFP)-encoding vector (pBMN-GFP;
Orbigen, San Diego, CA, USA) to produce D122-Luc/
GFP cells. D122-Luc/GFP cells were selected by treat-
ment with 3 μg/mL puromycin, followed by sorting of
fluorescent cells. Cells were maintained in 1 μg/mL
puromycin-contained media. Cells were used for immuno-
staining until the fifth passage.
Animal Dietary Protocol
Selenoglycoproteins were extracted from selenium-enriched
yeast at pH 4.0 and 6.5 (the fractions are called SeGP40 and
SeGP65, respectively). Control treatments included similarly
extracted glycoproteins from normal yeast, called GP40 and
GP65. Male C57BL/6 mice, 12 weeks of age (Jackson Labs,
Bar Harbor, ME, USA) were fed diets enriched with SeGP40,
SeGP65 (each containing 1 mg Se/kg), GP40, GP65 (each
containing 0.2–0.3 mg Se/kg), or a control diet (0.2–0.3 mg
Se/kg) for 12 weeks. Se supplementation, especially in the
form of organic forms, results in significant enrichment in
the brain [23]. Experimental diets were prepared based on
Teklad 2016 Base Diet by Harlan Laboratories (Indianapolis,
IN, USA), followed by an analysis of the final selenium
content.
All diets were provided ad libitum. SeGP and GP fractions
were obtained as described previously [22]. Briefly, the pro-
cess of SeGPs extraction from standardized Se-enriched yeast
was designed in order to capture and concentrate as many
water-soluble SeGPs as possible based upon the main pH
ranges of these species, namely pH 4.0 (SeGP40) and
pH 6.5 (SeGP65). The organic Se content, in the Se-
enriched yeast used for the extraction of the SeGPs was equal
to or greater than 98 % of total Se content. GP fractions were
obtained in the same manner from non-Se-enriched yeast.
Diets without Se enrichment (i.e., GP40 and GP65) were used
as controls for SeGP40 and SeGP65, respectively, in order to
evaluate the effect of Se and/or glycoprotein components. All
tested diets were isocaloric (3.1 Kcal/g) and equal in terms of
the content of protein, fat, and carbohydrates (16.2, 3.6, and
52.8%, respectively). Diet composition is provided in Table 1.
Body mass and food intake were monitored once a week
during the entire feeding period. Mice were euthanized with
carbon dioxide followed by decapitation. All procedures,
which complied with the guidelines of the American
Association for Accreditation of Animal Care (AAALAC),
were approved by the University of Miami Institutional
Animal Care and Use Committee.
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Table 1 Experimental diets
Control SeGP40 GP40 SeGP65 GP65
Macronutrients
Protein (% by weight) 16.2 16.2 16.2 16.2 16.2
Carbohydrate (% by weight) 52.8 52.8 52.8 52.8 52.8
Fat (% by weight) 3.6 3.6 3.6 3.6 3.6
Calorie content (Kcal/g) 3.1 3.1 3.1 3.1 3.1
Fiber (%) 3.3 3.3 3.3 3.3 3.3
Minerals
Calcium (%) 1.0 1.0 1.0 1.0 1.0
Non-phytate phosphorus (%) 0.4 0.4 0.4 0.4 0.4
Sodium (%) 0.2 0.2 0.2 0.2 0.2
Potassium (%) 0.6 0.6 0.6 0.6 0.6
Chloride (%) 0.4 0.4 0.4 0.4 0.4
Magnesium (%) 0.2 0.2 0.2 0.2 0.2
Zinc (mg/kg) 70 70 70 70 70
Manganese (mg/kg) 100 100 100 100 100
Copper (mg/kg) 15 15 15 15 15
Iodine (mg/kg) 6 6 6 6 6
Iron (mg/kg) 200 200 200 200 200
Selenium (mg/kg) 0.2–0.3 1.2–1.3 0.2–0.3 1.2–1.3 0.2–0.3
Amino acids
Aspartic acid (%) 1.0 1.0 1.0 1.0 1.0
Glutamic acid (%) 3.3 3.3 3.3 3.3 3.3
Alanine (%) 0.9 0.9 0.9 0.9 0.9
Glycine (%) 0.7 0.7 0.7 0.7 0.7
Threonine (%) 0.6 0.6 0.6 0.6 0.6
Proline (%) 1.5 1.5 1.5 1.5 1.5
Serine (%) 0.8 0.8 0.8 0.8 0.8
Leucine (%) 1.9 1.9 1.9 1.9 1.9
Isoleucine (%) 0.7 0.7 0.7 0.7 0.7
Valine (%) 0.8 0.8 0.8 0.8 0.8
Phenylalanine (%) 0.9 0.9 0.9 0.9 0.9
Tyrosine (%) 0.5 0.5 0.5 0.5 0.5
Methionine (%) 0.3 0.3 0.3 0.3 0.3
Cystine (%) 0.3 0.3 0.3 0.3 0.3
Lysine (%) 0.8 0.8 0.8 0.8 0.8
Histidine (%) 0.4 0.4 0.4 0.4 0.4
Arginine (%) 0.8 0.8 0.8 0.8 0.8
Tryptophan (%) 0.2 0.2 0.2 0.2 0.2
Vitamins
Vitamin A (IU/g) 15.0 15.0 15.0 15.0 15.0
Vitamin D3 (IU/g) 1.5 1.5 1.5 1.5 1.5
Vitamin E (IU/kg) 110.0 110.0 110.0 110.0 110.0
Vitamin K3 (mg/kg) 50.0 50.0 50.0 50.0 50.0
Vitamin B1 (mg/kg) 17.0 17.0 17.0 17.0 17.0
Vitamin B2 (mg/kg) 15.0 15.0 15.0 15.0 15.0
Niacin (mg/kg) 75.0 75.0 75.0 75.0 75.0
Vitamin B6 (mg/kg) 18.0 18.0 18.0 18.0 18.0
Pantothenic Acid (mg/kg) 33.0 33.0 33.0 33.0 33.0
Vitamin B12 (mg/kg) 0.1 0.1 0.1 0.1 0.1
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Tumor Cell Infusion, Timeline, and Bioluminescent
Imaging
At the conclusion of the feeding period, mice were randomly
assigned to vehicle or tumor groups. Mice were anesthetized
with isoflurane and 1.0×106 Lewis lung carcinoma D122-
Luc/GFP cells were slowly infused into the brain circulation.
The control/vehicle group was infused with cell culture medi-
um alone. Using the procedure standardized in our laboratory
[24], the common carotid artery was isolated along with the
internal and external carotid arteries. A 6-0 silk suture was
used to ligate the end of the external carotid artery distal to
the bifurcation point while the internal carotid artery and com-
mon carotid artery were temporarily closed with vessel clips.
A small incision was made in the external carotid artery prox-
imal to the bifurcation point of the common carotid artery and
tubing was inserted into the common carotid artery. After the
vessel clip was removed from the internal carotid artery, tumor
cell suspension or the vehicle was infused. The tubing was
removed and the external carotid artery was closed with a
second suture and the remaining vessel clip removed. Blood
flow returned and the surgical site was cleaned and closed.
The outcomes of the dietary supplementation and tumor
cell infusion were evaluated using two time points. For the
short-term studies, mice were euthanized 48 h post tumor cell
infusion, which coincides with transcapillary extravasation of
tumor cells. The second time point was 3 weeks post tumor
cell infusion (long-term studies), when brain metastases are
fully developed.
In the long-term study, the development of brain metastatic
nodules was monitored once a week using the IVIS Xenogen
Bioluminescence Imager (Caliper Life Sciences, Hopkinton,
MA, USA). Prior the measurements, both tumor and control
(vehicle) animals were anesthetized with isoflurane in oxygen
and injected ip with D-luciferin potassium salt (2 mg/100 μL)
to induce bioluminescence of D122-Luc cells. Identical instru-
ment settings were used for all measurements.
Plasma Selenium Concentration
Selenium content was analyzed using an inductively coupled
plasma mass spectrometer (ICP-MS) Agilent 7700 (Agilent
Technologies, Inc., Tokyo, Japan). Briefly, blood was collect-
ed by cardiac puncture into heparinized tubes and centrifuged
at 4 °C for 15min at 1000×g, followed by an additional spin at
10,000×g at 4 °C for 10min for complete platelet removal. All
standards and samples were prepared in buffer solution (4 %
butanol, 2 % ammonium hydroxide, 0.1 % EDTA, 0.1 %
Triton X-100). Buffer solution was dispensed into 15 mL cen-
trifuge tubes, and 250 μL of plasma was added. Samples were
analyzed in duplicate. Three replicates of reference material
BPlasma Control^ for trace elements, lyophilized, Level 1 (Se
certified value of 80 ng/mL±16 ng/mL, ClinChek®, RECIPE,
Munich, Germany) were prepared using the same procedure,
and were recovered at 98.72 %. Signal intensity was com-
pared to an external calibration curve prepared from a
1000 μg/mL Se standard (SCP-Science, New York, NY,
USA) over a 0.2–64 ng/mL dynamic range (R2 = 0.9993).
Diluted Rhodium (Rh, SCP-Science) was used as internal
standard at a concentration of 1 μg/mL.
Isolation of Brain Microvessel-Enriched Fraction
Brain microvessels were isolated as described earlier [25] with
modifications. The method allows for isolation of
microvessel-enriched fraction, with someminimal contamina-
tion from other cell types. Following decapitation, brains were
extracted and immediately immersed in ice-cold PBS. The
Table 1 (continued)
Control SeGP40 GP40 SeGP65 GP65
Biotin (mg/kg) 0.4 0.4 0.4 0.4 0.4
Folate (mg/kg) 4.0 4.0 4.0 4.0 4.0
Choline (mg/kg) 1030 1030 1030 1030 1030
Fatty acids
C16:0 palmitic (%) 0.5 0.5 0.5 0.5 0.5
C18:0 stearic (%) 0.1 0.1 0.1 0.1 0.1
C18:1ω9 oleic (%) 0.7 0.7 0.7 0.7 0.7
C18:2ω6 linoleic (%) 2.0 2.0 2.0 2.0 2.0
C18:3ω3 linolenic (%) 0.1 0.1 0.1 0.1 0.1
Total saturated (%) 0.6 0.6 0.6 0.6 0.6
Total monosaturated (%) 0.7 0.7 0.7 0.7 0.7
Total polyunsaturated (%) 2.1 2.1 2.1 2.1 2.1
Other
Cholesterol (mg/kg) – – – – –
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choroid plexus, meninges, cerebellum, and brain stem were
removed and the hemispheres were separated. The hemi-
sphere ipsilateral to tumor cell infusion was homogenized in
2 mL of ice-cold isolation buffer [102 mM NaCl, 4.7 mM
KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4,
15 mM HEPES, 25 mM NaHCO3, 10 mM glucose, 1 mM
Na pyruvate; pH 7.4 with Complete Protease Inhibitor
(Roche, Indianapolis, IN, USA)] and filtered through a
300-μm mesh filter (Spectrum Laboratories, Rancho
Dominguez, CA, USA). Then, 8 mL of 26 % dextran (molec-
ular weight 150 kD, Sigma, St. Louis, MO, USA) was added
to the homogenates, mixed well and samples were centrifuged
at 5800×g for 20 min at 4 °C. The supernatants were
discarded, and the pellets were resuspended in isolation buffer,
filtered through a 120-μm mesh filter (EMD Millipore,
Billerica, MA, USA) and repelleted by centrifugation
(1500×g for 10 min at 4 °C). Isolated microvessels were pre-
pared for immunofluorescent analysis or RNA extraction.
Immunofluorescent Staining
Brain microvessels were smeared on slides, fixed for 10min at
98 °C and then for additional 10 min at room temperature in
4 % paraformaldehyde. After washing 3 times with chilled
PBS, slides containing isolated microvessels were
permeablized with 0.1 % Triton X-100 (Sigma) for 30 min
at room temperature, then rinsed with PBS. Slides were
blocked using 3 % bovine serum albumin (BSA) in PBS for
1 h at room temperature followed by overnight incubation at
4 °C with anti-NF-κB p65 (acetyl K310, Abcam, Cambridge,
MA, USA) at 1:200 dilution. Following washes with PBS, α-
rabbit Alexa Fluor 488 (Invitrogen, Camarillo, CA, USA) was
applied at 1:400 dilution in 3 % BSA in PBS. After 90 min of
incubation at room temperature, protected from light, the
slides were washed and stained with DAPI (Cell Signaling,
Danvers, MA, USA) at 1 μg/mL concentration in PBS, to
visualize the nuclei. Slides were mounted with ProLong®
Diamond Antifade Mountant (Life Technologies). Images
were acquired using a Nikon Eclipse Ti-U fluorescence mi-
croscope and the NES Elements software.
Real-Time Quantitative Reverse Transcription PCR
RNA was extracted from brain microvessels using TRIzol
reagent (Life Technologies) according to the manufacturer’s
protocol. Reverse transcription was performed using the
Reverse Transcription System (Promega, Madison, WI,
USA). ICAM-1, VCAM-1 and ALCAM messenger RNA
(mRNA) levels were assessed using a 7500 Real Time PCR
System (Applied Biosystems, Foster City, CA, USA) and
TaqMan Universal PCR Master Mix. The primers and probes
were obtained from Applied Biosystems. The following
thermocycling conditions were used: 50 °C for 2 min,
followed by 95 °C for 10 min, 95 °C for 15 s, and 60 °C for
1 min for 40 cycles. The threshold cycle (CT) from each well
was determined using 7500 Software v2.0.5 from Applied
Biosystems. Expression of mRNAwas calculated by the com-
parative CT method. PCR amplification of GAPDH (house-
keeping gene) was performed for each sample to normalize
mRNA levels of the target genes. All samples were prepared
in triplicate.
Immunohistochemistry
Brains were fixed in 10 % formalin (EMDMillipore), embed-
ded into paraffin, and cut into a series of 5-μm thick sections
with 150-μm thick intersections. Sections were mounted onto
glass slides, deparaffinized, and subjected to antigen retrieval
in citrate buffer (pH 6.0). Endogenous peroxidase activity was
inhibited by treatment with 3 % H2O2 in methanol for 20 min.
The slides were rinsed in Tris-buffer saline containing 0.1 %
Triton X-100 (TBST), blocked with 5 % rabbit serum in
TBST, and incubated with chicken anti-GFP monoclonal an-
tibody (1:400; Aves Lab, Tigard, OR, USA) at 4 °C overnight,
followed by incubation with rabbit anti-chicken IgY-HRP sec-
ondary antibody (1:200; Abcam) for 1.5 h at room tempera-
ture. Diaminobenzidine (Vector Laboratories, Burlingame,
CA, USA) was used for color developing. The sections were
counterstained with hematoxylin (Sigma) and examined under
a light microscope (Nikon, Melville, NY, USA).
Statistical Analysis
The data were analyzed by one-way analysis of variance
(ANOVA) or two-wayANOVA,with Fisher’s least significant
difference (LSD) test. Data were further evaluated using
Dixon’s Q test. GraphPad Prism software (La Jolla, CA,
USA) was used for the analyses. Statistical probability of
p<0.05 was considered significant.
Results
Body Mass and Dietary Consumption of Different
Selenoglycoprotein/Glycoprotein Fractions
Mouse food intake and body mass were monitored once a
week during the entire 12-wk feeding period (Fig. 1a–b).
Although the average food intake varied from week to week,
there were no significant differences between the experimen-
tal groups (Fig. 1a). The plasma concentration of Se was mea-
sured before dietary supplementation and at the end of the
study. Baseline Se plasma concentration was ∼400 μg/L;
however, a 12-week supplementation with SeGP40 and
SeGP65 increased the concentration to 630–880 μg/L and
580–730 μg/L, respectively (Fig. 1e). Mice receiving diets
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supplemented with selenoglycoproteins had significantly
higher plasma Se levels.
Starting from week 4, the animals demonstrated progres-
sive weight gain and at the end of the feeding period all the
animals, regardless of diet, weighed approximately 15%more
than at week 0. There were no significant differences in animal
weight among the experimental and control groups (Fig. 1b).
During the first week after the surgery both vehicle and
tumor mice lost between 3 to 13 % of their body mass
(Fig. 1c–d). During the following 2 weeks, vehicle infused
mice increased their body mass, reaching to 90–95 % of their
initial weight by the third week (Fig. 1c). However, the body
mass of tumor cell infused mice continued to decrease, inde-
pendent of diet, reaching 82–87 % of their initial weight on
week 3 (Fig. 1d).
Selenoglycoprotein Fraction SeGP65 Attenuates Growth
of Metastatic Tumors in the Brain
In the long-term studies, the development of brain metastatic
nodules was monitored each week using live imaging. During
the first 2 weeks, brain tumor bioluminescence progressed
similarly in all experimental groups (Fig. 2a). At the third
week of monitoring, mice exposed to SeGP65 enriched diet
showed significantly diminished metastatic tumor growth as
compared to control (Fig. 2b-c). Mice that were not infused
with tumor cells exhibited bioluminescence at the background
levels.
To further characterize metastatic progression, the brains
were sectioned and stained for GFP-positive cells. Figure
3a–c are representative images of morphological changes ob-
served in the brain at different stages of metastatic tumor
growth in selected treatment groups. Specify, Fig. 3a provides
representative images of tumor cells attached to the brain en-
dothelium and/or in the perivascular space 48 h post tumor
cells infusion. Figure 3b and c show at different magnifica-
tions representative images of mature metastatic nodules,
growing 3 weeks post tumor cells infusion primarily in lateral
and third ventricles. Quantified results of these events, which
include all treatment groups, are shown in Fig. 3d–g. Solitary
tumor cells or tumor cells in micrometastases were counted

































Fig. 1 Body mass, dietary
consumption of different
selenoglycoprotein/glycoprotein
fractions and plasma Se concen-
trations. Mice were fed experi-
mental diets enriched with
SeGP40, G40, SeGP65, GP65, or
a control diet for 12 weeks. At the
conclusion of the feeding period,
mice were infused with 1.0 × 106
D122-Luc/GFP cells in culture
medium (tumor mice) or with
culture medium alone (vehicle
mice). a Food intake and bweight
change were monitored once a
week during the feeding period.
After surgery, body mass was
measured once per week up to the
third week in c vehicle or d
tumor-infused mice. e Plasma Se
concentration measured before
the dietary supplementation
(Baseline) and after 12 week
feeding period with indicated di-
ets. Values are mean± SEM.,
n= 32 mice per group (a and b),
n= 10 mice per group (c and d),
n= 4 (e). Significantly different as
compared with control at
***p< 0.001 or *p< 0.05, one-
way ANOVA
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At 48 h post tumor cell infusion, there was a significant re-
duction (∼30 %) in the number of solitary tumor cells in mice
fed SeGP65 enriched diet as compared with mice fed control
diet and infused with tumor cells (Fig. 3d). Furthermore, there
was a significant reduction (∼30 %) in the number of solitary
tumor cells in SeGP65 fed mice as compared to GP65 fed
mice, suggesting a significant contribution of Se. Following
3 weeks of tumor growth, there were no significant differences
in the number of solitary tumors cells or the number of meta-
static nodules among mice fed any of the experimental diets
(Fig. 3e and f). SeGP40 showed trends towards reduced num-
ber of solitary tumor cells (Fig. 3e) and reduction of metastatic
nodules (Fig. 3g); however, the results did not reach signifi-
cance. Importantly, feeding mice with SeGP65-enriched diet
significantly reduced the size of metastatic nodules by more
than 50 % (Fig. 3g).
Supplementation with Selenoglycoprotein Fractions
Alters Gene Expression of Selected Adhesion Molecules
in Brain Microvessels
The effects of selenoglycoproteins and tumor cell infusion on
the expression of selected cell adhesion molecules, namely
ICAM-1, VCAM-1, and ALCAM, were evaluated by quanti-
tative reverse transcription PCR. Infusion of tumor cells sig-
nificantly upregulated ICAM-1 mRNA levels within all die-
tary treatments except for GP40 (48-h time point) and SeGP65
(3 week time point) (Fig. 4a–b). There was also a significant
interaction between diets and tumor cell infusion on ICAM-1
mRNA expression at 48 hr. VCAM-1 mRNA levels were
similarly upregulated with tumor cell infusion for all diets
except SeGP65 at 48 h post tumor cell infusion (Fig. 4c).
Following 3 weeks of tumor growth, VCAM-1 mRNA levels
were at the control levels in mice fed all experimental diets,
except the SeGP65 fed group, which exhibited a significant
decrease in VCAM-1 mRNA levels compared with both con-
trol tumor and the GP65 control (Fig. 4d). There was a signif-
icant interaction between dietary treatment and tumor cell in-
fusion on VCAM-1 mRNA expression. ALCAM mRNA
levels showed significant upregulation at a 48-h time point
in the tumor cell infused mice for all dietary group except
the SeGP65 fed group, where the differences were not signif-
icant (Fig. 4e). ALCAM expression was not changed 3 weeks
post tumor cell infusion for all dietary treatments except
SeGP40, which increased expression of this adhesion mole-
cule (Fig. 4f). At both 48 h and 3 weeks post tumor cell
infusion, there was a significant interaction between diet and
tumor cell infusion on ALCAM mRNA levels.
Selenoglycoprotein Fraction SeGP65 Decreases
Expression of Acetylated NF-κB p65 in Brain
Microvessels 48 h Post Tumor Cell Infusion
The effects of Se-containing compounds and tumor cell infu-
sion on the expression of acetylated NF-κB p65 in brain
microvessels were assessed by immunofluorescence micros-















Fig. 2 In vivo monitoring of brain metastatic progression. The
development of brain metastatic nodules was monitored each week
using the IVIS Xenogen Bioluminescence Imager based on the
bioluminescent signal from D122-Luc/GFP tumor cells. a Quantified
results of tumor progression over 3 weeks of observation. b Quantified
bioluminescent signal for each dietary group at the third (final) week after
tumor cell infusion. c Representative images at weeks 2 and 3 after tumor
cell infusion. Values are mean ± SEM., n= 13–15 mice per group. *Sig-
nificantly different as compared with mice fed control diet at *p < 0.05,
one-way ANOVA
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microvessel-enriched fraction, with someminimal contamina-
tion from other cell types. Example of a microvessel was
outlined in Fig. 5a. Translocation of acetylated NF-κB p65
only to the nuclei associated with microvessels was quanti-
fied. The nuclei were stained by DAPI and the right column
reflects merged images of acetylated NF-κB p65 and DAPI.
Infusion of tumor cells significantly increased (by ∼50–
100 %) expression of NF-κB p65 (acetyl Lys-310) within all
dietary treatments, except for SeGP65. Instead, mice fed
SeGP65 enriched diet and infused with tumor cells displayed
significant reduction (by ∼60 %) in expression of acetylated
form of NF-κB p65 in brain microvessels as compared to
control tumor group (Fig. 5b). Furthermore, SeGP65 vehicle
group showed significant decrease (by ∼40 %) in expression
of NF-κB p65 (acetyl Lys-310) when compared with vehicle-
treated control (Fig. 5b).
Discussion
Diet and physical activity are crucial behavioral factors mod-
ulating cancer risk and possibly affecting tumor progression
Fig. 3 Immunohistochemical
analysis of tumor growth in the
brain. Tumor progression was
evaluated by staining of brain
sections for GFP-positive cells
48 h and 3 weeks post tumor cell
infusion (TCI). a Representative
histological images of solitary tu-
mor cells or tumor cells in small
clusters at 20× and 40× magnifi-
cation 48 h post tumor cell infu-
sion. b Representative images of
metastatic nodules measured at
10× magnification present mainly
in lateral and third ventricles
3 weeks post tumor cell infusion.
c Representative coronal sections
at 1.25× magnification showing
metastatic nodules 3 weeks post
tumor cell infusion. a–c Arrows
indicate GFP-positive cells, clus-
ters, and nodules. dMean number
of solitary tumor cells (per slide)
48 h and e 3 weeks post TCI. f
Mean number of metastatic nod-
ules (per slide) and g metastatic
area 3 weeks post TCI. Values are
mean ± SEM, n= 4–6 mice per
group. *Significantly different as
compared with mice fed control
diet at *p< 0.05. #Values in the
group SeGP65 are significantly
different as compared with those
in the GP65 group at #p< 0.05,
one-way ANOVA
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[26, 27]. Previously, we investigated a nutritional-based inter-
vention specifically targeting adhesion and tumor cell migra-
tion of tumor cells in vitro. We demonstrated effectiveness of
specific selenoglycoproteins to diminish these events and in-
hibit early stages of cancer progression [22]. Based on these
findings, we explored in the present study whether
selenoglycoproteins incorporated into standard chow could
modulate brain metastatic progression in mice.
Initially considered a toxic and potentially carcinogenic
element, Se was recognized in the second half of the twentieth
century as an essential nutrient with a significant role in hu-
man health and well being [28, 29]. It has been reported by
numerous epidemiological studies that low Se status is asso-
ciated with increased risk of certain types of cancer in terms of
incidence and mortality [30–32]. Indeed, anticancer properties
of Se have been demonstrated in various laboratory studies,
including carcinogenesis experiments based on different ani-
mal models, with most of them showing a significant decrease
in cancer incidence [33, 34]. In spite of the scientific evidence
demonstrating the anticancer properties of Se, inconsistent
results from clinical trials have lessened the initial
recommendations for Se supplementation [19, 35, 36].
Recently, it has been pointed out that the contradictory find-
ings might be due to the lack of understanding of the mecha-
nisms underlying Se biology [37]. Furthermore, growing ev-
idence indicates that anticancer effects of Se supplementation
depend not only on the dose and biological form of Se and
cancer type, but also on the baseline Se status of the popula-
tion. Beneficial effects of Se supplementation should be ex-
pected only when the Se levels prior to supplementation are
low or suboptimal [13, 38, 39].
While most of the studies have investigated the relation of
Se and cancer prevention, distinctly less attention has been
given to cancer progression and metastasis. The metastatic
model employed in our study was based on the infusion of
Lewis lung carcinoma cells into the brain microvasculature, as
lung cancers represent one of the most common primary tu-
mors creating secondary lesions in the brain [3, 40]. The re-
sults indicate that supplementation with specific
selenoglycoproteins can modulate tumor cell homing in
mouse brain. Tumor progression in the brain as measured by
in vivo imaging as well as post hoc immunohistochemical
Fig. 4 Supplementation with
selenoglycoprotein fractions
alters gene expression of selected
adhesion molecules in brain
microvessels. mRNA levels of
adhesion molecule following
dietary supplementation and
tumor cell infusion as measured
by RT-PCR. ICAM-1 mRNA
levels a 48 h and b 3 weeks post
surgery. VCAM-1mRNA levels c
48 h and d 3 weeks post tumor
cell or vehicle infusion. ALCAM
mRNA levels e 48 h and f
3 weeks post tumor cell or vehicle
infusion. Values are mean ± SEM,
n = 4–7 mice per group. Signifi-
cantly different as compared with
control vehicle mice at
***p< 0.001, **p< 0.01 or
*p< 0.05. Significantly different
as compared with control tumor
mice at !!!p< 0.001, !!p< 0.01 or
!p < 0.05. Significantly different
as indicated at #p< 0.05, two-way
ANOVA



























NF- κB p65/DAPIFig. 5 Selenoglycoprotein
fraction SeGP65 decreases
expression of acetylated NF-κB
p65 in brain microvessels 48 h
post tumor cell infusion. a
Representative
immunofluorescent images of
brain microvessels isolated 48 h
after tumor cell or vehicle
infusion, stained for NF-κB p65
(acetyl Lys-310) Alexa Fluor488
(green), and DAPI (blue)
counterstaining. b Quantified
fluorescent signal measured from
the nuclei of isolated
microvessels. Images were
acquired using a 40× lens. Values
are mean ± SEM, n= 3–4 mice
per group. Significantly different
as compared between vehicle and
tumor within dietary treatment at
***p< 0.001, **p< 0.01, or
*p< 0.05. Significantly different
as compared with control tumor
mice at !!p< 0.01. Significantly
different as compared with
control vehicle mice at #p< 0.05,
two-way ANOVA
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staining revealed similar trends implicating Se as a potential
regulator of the metastatic process. Indeed, previous reports
have indicated attenuation of lung and liver metastatic tumors
growth following Se supplementation [41–43].
It has been shown that the beneficial effects of Se on cancer
metastasis largely depend on the chemical form [11, 41].
Although Se can be supplemented as organic or inorganic
compounds, each possessing anticancer properties, the inor-
ganic forms of Se show lower rates of absorption, tissue ac-
cumulation, and antioxidant bioavailability as compared to
organic forms [44]. In our previously published study [18],
we compared the properties of several Se compounds, includ-
ing L-selenomethionine, sodium selenite, and Se-enriched
yeast formulation, on the development of melanoma brain
metastatic lesions. Our results indicated that mice bearing
brain metastatic tumors and fed Se-yeast-enriched diet
displayed a higher survival rate and decreased tumor growth
as compared to controls. Another study revealed that
selenomethionine could attenuate or delay breast cancer me-
tastasis in mice, whereas selenite did not provide protection
[41]. These protective effects of organic Se-yeast formulation,
where selenomethionine was the primary source of Se, as well
as selenomethionine itself, may be attributed to non-specific
incorporation of selenomethionine into the general body pro-
teins. Since selenomethionine is readily stored in the organ-
ism, treatment with selenomethionine provides an advantage
over dietary supplementation with other Se compounds [44,
45]. For example, i t has been demonstrated that
selenomethionine-supplemented animals maintained higher
activity of selenoenzymes during Se depletion for longer pe-
riods than selenite-supplemented animals [45]. In our study,
both SeGP40 and SeGP65 were extracted from Se-enriched
yeast and contain mostly organic Se [18, 22]. The process of
SeGP extraction was designed to capture specific water-
soluble SeGP fractions and was based on the main pH ranges
of these species [22]. This distinct composition of SeGP40
and SeGP65 translates into their different biological activities.
Although SeGP40 showed some trends towards reduced brain
metastatic tumor growth, the results did not reach significance.
It is likely that distinct SeGPs employ different molecular
pathways that lead to modulation of tumor progression in
the brain.
Consistent with reports suggesting that the form of Se plays
a role, the present study demonstrates that supplementation
with selected selenoglycoproteins, mainly SeGP65, can mod-
ulate mRNA levels of specific pro-inflammatory adhesion
molecules. The adhesion molecules evaluated in this study,
namely ICAM-1, VCAM-1 and ALCAM, are known to be
involved in tumor cell attachment to the vascular endothelium
and are directly implicated in the progression of tumor growth,
including early stages of metastasis seeding in the brain [3,
46]. In the early stage of tumor progression, i.e., 48 h post
tumor cell infusion; all studied adhesion molecules were
significantly upregulated (as much as fourfold). Only
microvessels isolated from SeGP65 supplemented mice
showed no difference with tumor cell infusion in VCAM-1
and ALCAM mRNA levels, indicating a potential protective
effect. Importantly, the positive effects of SeGP65 were also
maintained in mice with mature tumors, i.e., 3 weeks of tumor
growth, when ICAM-1 mRNA levels were still elevated with-
in most treatment groups and SeGP65 fed mice alone showed
no change with tumor cell infusion.
Interesting results were observed when analyzing the im-
pact of GP40 supplementation on tumor cell-induced upregu-
lation of ICAM-1. GP40 was the only fraction which
protected against ICAM-1 mRNA increase 48 h post tumor
cell infusion. However, these effects were not sustained fol-
lowing 3 weeks of tumor growth, with ICAM-1 mRNA levels
being highly elevated in GP40-fed mice with mature tumors.
Based on these observations, the impact of specific GPs and
SeGPs on expression of ICAM-1 in brain microvessels ap-
pears to be dependent on the stage of tumor growth.
Furthermore, these results suggest a potential role of the gly-
coprotein component in modulating the adhesive properties of
brain microvasculature. While the most effective in modulat-
ing tumor cell progression in the brain were Se containing
fractions, the current results as well as our previously pub-
lished data [22] suggest the role of not only Se, but also gly-
coproteins in the observed effects.
An inducible transcription factor, NF-κB is a key regulator
of inflammatory, immune, and antiapoptotic responses in
mammalian cells [47]. To reach full biological activity
NF-κBmust undergo several post-translational modifications,
including intranuclear, reversible acetylation of distinct lysine
residues in the p65 subunit [48]. Acetylation of p65 is crucial
for modulating NF-κB nuclear functions and has been shown
to enhance its DNA binding and transcriptional activities. In
contrast, deacetylation stimulates binding of endogenous in-
hibitor IκBα and promotes rapid nuclear export of the NF-κB
complex [48–50]. In our current study infusion of tumor cells
robustly increased the acetylation status of NF-κB p65 in the
nuclei of isolated microvessels. Importantly, supplementation
with SeGP65, but not glycoprotein fractions, significantly re-
duced baseline acetyl-NF-κB p65 expression and attenuated
tumor cell-induced activation of this transcription factor.
These results are consistent with the impact of SeGP65 on
the expression of adhesion molecules evaluated in this study.
Indeed, NF-κB is known to play an essential role in pro-
inflammatory activation of human endothelium, including ex-
pression of cell adhesion molecules [51, 52].
Tumor cells are known to produce high levels of reac-
tive oxygen species (ROS) [53]. We also reported that
extravasation and growth of brain metastatic tumors are
related to oxidative stress [26]. It has been demonstrated
that pro-inflammatory activation of vascular endothelium,
characterized by activation of various transcription
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factors, including NF-κB, and upregulation of adhesion
molecules, results from an increase in ROS [54].
Selenium is a crucial cofactor for several important anti-
oxidative enzyme systems, including glutathione peroxi-
dase (GPx), and anticancer effects of Se are largely attrib-
uted to its ability to modulate oxidative stress [12, 14,
53]. GPx, along with several other selenoproteins, have
been detected in human and rodent brains [9, 55] and
may modulate, at least in part, the effects observed in
the present study. To support this notion, it has been re-
ported that GPx deficiency stimulates expression of vari-
ous adhesion molecules on the endothelial cell surface
[54, 56].
In conclusion, our study indicates that specific
selenoglycoproteins may be considered as possible candidates
for adjuvant therapies aiming at suppression of brain metasta-
tic tumor growth by modulating adhesive properties of brain
vascular endothelium. These results further warrant the devel-
opment of novel tumor targeted Se compounds or supple-
ments tailored for cancer and metastasis prevention.
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